Procalcitonin-Guided Use of Antibiotics for Lower Respiratory Tract Infection
New England Journal of Medicine2018Vol. 379(3), pp. 236–249
Citations Over TimeTop 1% of 2018 papers
David T. Huang, Donald M. Yealy, Michael R. Filbin, Aaron Brown, Chung‐Chou H. Chang, Yohei Doi, Michael W. Donnino, Jonathan Fine, Michael J. Fine, Michelle A. Fischer, John M. Holst, Peter C. Hou, John A. Kellum, Feras Khan, Michael C. Kurz, Shahram Lotfipour, Frank LoVecchio, Octavia M. Peck‐Palmer, Francis Pike, Heather A. Prunty, Robert Sherwin, Lauren T. Southerland, Thomas E. Terndrup, Lisa A. Weissfeld, Jonathan G. Yabes, Derek C. Angus
Abstract
The provision of procalcitonin assay results, along with instructions on their interpretation, to emergency department and hospital-based clinicians did not result in less use of antibiotics than did usual care among patients with suspected lower respiratory tract infection. (Funded by the National Institute of General Medical Sciences; ProACT ClinicalTrials.gov number, NCT02130986 .).
Related Papers
- Procalcitonin versus C-reactive protein for predicting pneumonia in adults with lower respiratory tract infection in primary care.(2007)
- → Use of infection biomarkers in the emergency department(2022)9 cited
- Diagnostic value of procalcitonin and C-reactive protein for gram-negative bacteria-caused lower respiratory tract infection in elderly patients(2014)
- → Clinical significance of joint detection of procalcitonin, erythrocyte sedimentation rate, and C-reactive protein in lower respiratory infection(2013)
- → Diagnostic value of serum procalcitonin and C-reactive protein in patients with lower respiratory tract diseases(2014)